“…Radiopharmaceuticals targeting the prostate-specific membrane antigen (PSMA) have seen great success in Nuclear Medicine for both diagnosis and endoradiotherapy of prostate cancer (PCa) [ 1 , 2 ] thus paving the way for (radio)theranostics [ 3 , 4 , 5 ] with guidelines being published by international experts and societies [ 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 ].…”